March 25th 2025
Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.
2 Year Data on Lenacapavir Reinforces Clinical Profile for Adults With Multi-Drug Resistant HIV
October 21st 2023The antiretroviral, lenacapavir (Sunlenca 463.5 mg/1.5 mL injection), had reported resistance in only a minority of study participants according to the latest findings released at a conference.
Read More
WHO Updates Recommendations for HIV, Hepatitis, STI Interventions in Prisons
July 26th 2023The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.
Read More
Long-Acting HIV Injectable Preferable to Daily Oral Regimen
July 24th 2023A new study being presented at the ongoing IAS conference showed that people with HIV found the injectable therapy, Cabotegravir plus long-acting Rilpivirine (Cabenuva) is more conducive to today’s lifestyles, reduced stigma, and improved adherence.
Watch
Prophylactic Statin Therapy Can Reduce Cardiovascular Events in People with HIV
July 24th 2023A new study shows the use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events. The data is being reported at the International AIDS Society Conference.
Read More
Almost Zero Risk of Sexually Transmitting HIV From People on ART with Low Levels of Virus
July 23rd 2023New study demonstrates benefit of adhering to treatment regimen and also calls for simplifying viral testing in other parts of the world where updated panels technology may not be available.
Read More
Disparities in HIV Prevention: New Data Reveal Racial and Regional Gaps in PrEP Usage
June 28th 2023New data from AIDSVu show significant disparities in the usage of HIV pre-exposure prophylaxis (PrEP). Black and Hispanic/Latinx Americans are underrepresented among PrEP users, despite accounting for a significant portion of new HIV diagnoses.
Read More